Everything tagged "valuation" across research, earnings, and macro.
145 articles
Skyworks looks like more than a dead-cat bounce after its May earnings beat and a disclosed Android program worth more than $1 billion through 2030. The one-customer risk is still real, but the market is finally pricing in evidence that the business may be broadening faster than bears expected.
Futu’s 27.5% one-day collapse looks like the market pricing a permanent break in the business, and that narrative is missing one crucial number: mainland China funded accounts were about 13% of the total as of Q1 2026. If next week’s Q1 report shows the rest of the platform is still compounding the way 2025 did, this washout looks more like panic than thesis destruction.
Nvidia’s latest earnings kept the AI spending boom intact, but the stock’s muted reaction said something more important: the market is no longer paying up just for obvious exposure. From here, the better trade looks like selective owners of AI bottlenecks and monetization layers, not simply adding to the biggest GPU winner.
Spotify is pairing double-digit user growth with rising margins and strong cash generation. The stock looks like a quality compounder, but valuation leaves less room for error.
Walmart is still a very good business, but the stock was priced like a flawless one. Once softer EPS guidance and fresh margin pressure showed up, that premium had nowhere to hide.
Rising Treasury yields have stopped being background noise for the market’s most crowded growth names. With the 10-year at 4.631%, the 30-year above 5%, and AI leaders still priced for near-perfect execution, duration risk is starting to bite where positioning is most crowded.
Amer Sports is compounding quickly as Arc’teryx and Salomon drive double-digit growth, margin expansion, and a higher-quality mix. The stock looks attractive on fundamentals, but valuation and execution risk keep it in buy-on-quality territory.
Agilysys is compounding revenue, expanding margins, and deepening its recurring mix across hospitality software. The stock looks high quality, but the valuation still leaves limited room for execution missteps.
Nebius is emerging as a pure-play AI infrastructure winner, with revenue up 479% in 2025 and capacity already sold out. The upside is real, but the stock trades at a premium that demands near-perfect execution.
Insmed has evolved into a commercial-stage rare respiratory company with two marketed products and a fast-scaling launch. BRINSUPRI is driving the revenue inflection, while ARIKAYCE and a late-stage pipeline add durability and upside.
D-Wave posted 179% FY2025 revenue growth, 82.6% gross margin, and $884.5M in cash, but the stock still trades at a steep valuation. The report rates QBTS a Buy, with commercialization traction offset by ongoing losses and execution risk.
Carvana has shifted from restructuring to execution, with revenue, margins, and profitability all surging in 2025 and Q1 2026. The main debate is whether the stock’s premium valuation already discounts too much of the turnaround.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator